iRadimed Corp Aktie News

WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed's unique position a...

IRADIMED CORPORATION (NASDAQ:IRMD ) Q1 2025 Earnings Conference Call May 5, 2025 9:00 AM ET Company Participants Roger Susi - Founder, President & CEO John Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Welcome to the IRADIMED Corporation First Quarter of 2025 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024. Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, re...

WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ: IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025".  The corrected release follows:

WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions.

IRadimed Corporation offers steady revenue growth with 14 consecutive quarters of record revenue and a small dividend, despite recent stock price decline. IRMD's unique MRI-compatible IV infusion pump and patient monitoring system face limited competition, ensuring a strong market position. Financials show robust performance with a 21% increase in US sales, but international sales dipped possib...

WINTER SPRINGS, Fla., March 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that it will participate in the 37 th Annual Roth Conference.

IRADIMED CORPORATION (NASDAQ:IRMD ) Q4 2024 Earnings Conference Call February 13, 2025 11:00 AM ET Company Participants Roger Susi - Founder, President and CEO John Glenn - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH Capital Partners Nelson Cox - Lake Street Capital Markets Operator Welcome to the IRADIMED CORPORATION Fourth Quarter of 2024 Financial Results Confere...